A Phase I/II Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with Receptor Tyrosine Kinase Inhibitor Resistant Renal Cell Carcinoma
Latest Information Update: 21 Feb 2025
Price :
$35 *
At a glance
- Drugs Bicalutamide (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 17 Feb 2025 Planned End Date changed from 1 Jul 2026 to 1 Jul 2027.
- 17 Feb 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Jul 2026.
- 17 Feb 2025 Status changed from not yet recruiting to recruiting.